Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
none appears on more than one · 1 vehicle carry no counterparty filing we have read
Dr. James Zhao-Hui Zhang (張朝暉) serves as the independent director appointee of Ribbon Acquisition Corp (RIBB), a SPAC sponsored by Ribbon Ventures Ltd. and based in Tokyo, Japan. He brings nearly three decades of experience spanning biotechnology, venture capital, and financial services. According to Bloomberg, he holds a board seat at Ribbon Acquisition Corp, and the company's SEC filings and leadership page confirm his role as independent director appointee. His business address is listed as c/o Ribbon Acquisition Corp at Central Park Tower LaTour Shinjuku, Tokyo.
In his academic career, Dr. Zhang holds the positions of Adjunct Associate Professor of Management at the Chinese University of Hong Kong (CUHK) Business School, Adjunct Associate Professor of Finance at the Hong Kong University of Science and Technology (HKUST), and Associate Professor of Science Practice at HKUST. He currently serves as Advisor to the Chairman and former Chief Investment Officer of Great Eagle Holdings, a major Hong Kong conglomerate. Additionally, he is a Partner at VU Venture Partners and a Venture Partner of the GRC Fund, as well as a venture partner at Venture University.
Dr. Zhang was a co-founder and partner of Formation 8, a Silicon Valley-based venture capital firm with over one billion dollars under management that was an early backer of unicorns including Oculus VR, Wish.com, Oscar Health, OpenGov, and Blend Labs. Prior to co-founding Formation 8, he served as a Venture Partner at Softbank China Venture Capital and at Khosla Ventures, two of the most prominent venture capital firms in Greater China and the United States, respectively. As a biotechnologist, he co-founded several biotechnology companies in both China and the US, including Modular Bioscience, BioConsortia, and Mendel Biotechnology, all based in Silicon Valley. His notable investments also include LanzaTech and Rancher Labs. He has an extensive publication record in plant biology and genomics, with papers appearing in Science, Proceedings of the National Academy of Sciences, Plant Physiology, and other leading journals.
Dr. Zhang earned his B.S. in Biology from the University of Science and Technology of China, a Ph.D. in Genetics from the University of California, Davis, and completed a post-doctorate at Stanford University along with business studies at Stanford Graduate School of Business. He is based in Hong Kong and is affiliated with Great Eagle Group and HKUST.
This record is keyed to SEC CIK 0002001945 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 23 institutional-holder rows on these vehicles, under 17 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.